Recent MI, coronary stents and antiplatelet therapy
Stem
A 64-year-old man, 88 kg, has a newly diagnosed colon cancer and is scheduled for open right hemicolectomy in three weeks. Four months ago he had a non-ST-elevation MI treated with a drug-eluting stent to the left anterior descending artery. He takes aspirin and ticagrelor, has no angina, and his ejection fraction is 50%. The surgeon asks you to stop "the blood thinners" and place an epidural.
Question
How will you manage his antiplatelet therapy and plan his anesthetic?
Ideal answer
HeadlineA drug-eluting stent for an acute coronary syndrome four months ago: too early for elective surgery, acceptable for time-sensitive cancer surgery, on aspirin, without an epidural.
- Stent type, date, indication, and surgical bleeding risk. Elective waits at least 30 days after bare-metal, 6 months after drug-eluting for stable disease, 12 months after one for ACS; MI without a stent, 60 days.1
- Cancer resection is time-sensitive: considered from 3 months.1 His qualifies.
- Aspirin throughout; ticagrelor held 3 days,1 the shortest hold the surgeon accepts, agreed with his cardiologist.1
- No epidural: general with other analgesia, because ASRA requires 5 days off ticagrelor before a neuraxial block.2
- A hospital with a catheterization laboratory around the clock, because stent thrombosis is treated by emergency PCI, not thrombolysis.
Watch for: hemostasis; ticagrelor restarts with a loading dose within 24–72 hours of surgery.
Breaking down the answer
- Why the delays — a bare-metal stent endothelializes in about a month; a drug-eluting stent delays it, and thrombosis risk falls steeply over the first 6 months.3 ACS or a complex stent (bifurcation, long or multivessel) carries higher risk, hence 12 months.
- Inside the window — within 30 days of any stent, interrupting antiplatelet therapy for elective surgery is harmful; unavoidable surgery within 30 days of bare-metal or 3 months of drug-eluting stenting proceeds on both drugs where possible.1 Examiners want that committed to.
- Aspirin continues — advised in every stented patient, whatever the stent type or age, when bleeding risk allows;1 it reduces stent thrombosis at a minor bleeding cost. Changes if: intracranial, posterior-eye, spinal canal or prostate surgery, the surgeon insists and the stent is old.
- Bridging is not a solution — heparin does nothing for platelet-mediated stent thrombosis; cangrelor or a glycoprotein IIb/IIIa infusion is a bridge I use only with cardiology for the highest-risk stents when surgery truly cannot wait.
- Clopidogrel and prasugrel — clopidogrel off 5–7 days and prasugrel 7–10 days before neuraxial;2 aspirin monotherapy is acceptable;4 a continuing P2Y12 inhibitor means general anesthesia.
- Monitoring and blood — five-lead ECG with ST analysis on II and V5, an arterial line for high-risk surgery, hemoglobin above 8 g/dL because anemia converts a fixed stenosis into ischemia; cell salvage and tranexamic acid offset continued aspirin.
Follow-up question
Two hours after surgery, on aspirin alone, he develops ST elevation in leads II, III and aVF, hypotension and ventricular ectopy. What do you do?
Follow-up answer
HeadlineAcute stent thrombosis. I call for help, give 100% oxygen and activate the catheterization laboratory immediately.
The only effective treatment is mechanical reopening of the stent. Phenylephrine or norepinephrine maintain coronary perfusion; amiodarone and defibrillation as needed for ventricular arrhythmias. I tell the surgeon that systemic thrombolysis is not an option and that the bleeding risk of heparin and a glycoprotein IIb/IIIa inhibitor in the laboratory is accepted; the alternative is losing the myocardium. I keep watching the abdomen and the hemoglobin, and reassess rhythm and pressure continuously until he is on the table in the laboratory.
Pitfalls that cost points
- Reciting the old blanket rule of a year for every drug-eluting stent.
- Stopping aspirin reflexively because "the patient is having surgery."
Rapid-fire
Q: Why is a drug-eluting stent slower to endothelialize? A: The antiproliferative drug that prevents restenosis also delays endothelial coverage of the struts, leaving metal exposed to platelets for months.
Q: Why does surgery itself raise thrombosis risk? A: Surgical stress increases platelet reactivity and catecholamines and lowers fibrinolysis; combined with withdrawal of antiplatelet therapy, a recognized cause of stent thrombosis,3 the stent is at its most vulnerable.
Q: Why does ticagrelor need a shorter stop than prasugrel? A: Ticagrelor binds reversibly, so platelet function recovers as the drug clears; prasugrel and clopidogrel bind irreversibly and recovery waits for new platelets.
Q: What if a patient is on aspirin and a P2Y12 inhibitor for a stent placed three weeks ago and needs an emergency appendectomy? A: I proceed on both drugs, accept the bleeding, use tranexamic acid, keep platelets available, and have the catheterization laboratory on notice.
Q: The surgeon demands you stop aspirin for a hernia repair. What do you say? A: The thrombosis risk outweighs the bleeding risk, and I will not stop it without the cardiologist's agreement.
Numbers to know
| Item | Value |
|---|---|
| Bare-metal stent, elective surgery | ≥30 days1 |
| Drug-eluting stent, elective surgery | ≥6 months for stable disease; ≥12 months after ACS; ≥3 months if time-sensitive1 |
| MI without revascularization | ≥60 days1 |
| Clopidogrel / ticagrelor / prasugrel hold | 5 / 3 / 7 days before surgery1 (ASRA neuraxial: 5–7 / 5 / 7–10)2 |
| Restart P2Y12 inhibitor | 24–72 h postoperatively, with loading dose |
| Aspirin before neuraxial block | Continue; safe as monotherapy4 |
Links
- Preoperative cardiac evaluation for non-cardiac surgery, Perioperative myocardial ischemia and infarction, Neuraxial blocks and anticoagulants (ASRA), ACLS adapted to the operating room, Intraoperative cardiac arrest: care after return of circulation
- ACC/AHA 2024 perioperative cardiovascular guideline; ASRA Regional Anesthesia in the Patient Receiving Antithrombotic Therapy, 5th edition
Sources
- 1.2024 ACC/AHA guideline on perioperative cardiovascular management before noncardiac surgery: What's new? · Cleveland Clinic Journal of Medicine, 2025 · ccjm.orgCohn SL, CCJM 92(4), April 2025. Stent timing, DAPT and P2Y12 hold intervals from the 2024 AHA/ACC guideline; primary guideline text was not reachable from the fetcher.
- 2.ASRA Guidelines for Regional Anesthesia with Antithrombotic or Thrombolytic Therapy 5th Edition - Summary of Recommendations · Guideline Central / ASRA Pain Medicine, 2025 · guidelinecentral.comVerbatim recommendation list of the fifth edition, produced in participation with ASRA; used here for the neuraxial P2Y12 intervals.
- 3.Percutaneous Coronary Interventions (PCI) · Merck Manual Professional Edition · merckmanuals.com
- 4.Perioperative Management of Patients on Antiplatelet Medication (Elective Surgery) · NHS Lanarkshire, 2026 · rightdecisions.scot.nhs.ukLocal UK guideline; used only for aspirin monotherapy being acceptable with neuraxial techniques.
Facts on this page were checked against these sources on Oct 14, 2026. Guidelines change; confirm doses against current institutional protocols.